An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study
- PMID: 772461
- DOI: 10.1212/wnl.26.5.441
An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study
Abstract
Baclofen (a gamma aminobutylic acid derivative) and a placebo were compared for their efficacy in relieving certain symptoms in patients with long-standing spinal cord lesions and "spinal spasticity." In a double-blind, cross-over clinical investigation, 22 patients with chronic spinal cord disease were studied. Baclofen regularly alleviated involuntary flexor or extensor spasms and increased resistance to passive movement of the legs but did not alter strength, gait, stretch reflexes, or clonus. Side effects were mild and transient. This study demonstrates that (1) baclofen is useful for the treatment of flexor spasms and (2) in evaluating a new mode of therapy, one must consider selectively the response of individual components of such global syndromes as "spasticity."
Similar articles
-
A benefit-risk assessment of baclofen in severe spinal spasticity.Drug Saf. 2004;27(11):799-818. doi: 10.2165/00002018-200427110-00004. Drug Saf. 2004. PMID: 15350152 Review.
-
Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis.Arch Neurol. 1977 Jul;34(7):422-8. doi: 10.1001/archneur.1977.00500190056008. Arch Neurol. 1977. PMID: 327987 Clinical Trial.
-
Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study.Clin J Pain. 1992 Dec;8(4):338-45. Clin J Pain. 1992. PMID: 1493344 Clinical Trial.
-
[Clinico-quatitative evaluation of the action of Ciba 34.647-Ba on spasticity].Arq Neuropsiquiatr. 1977 Dec;35(4):354-61. doi: 10.1590/s0004-282x1977000400008. Arq Neuropsiquiatr. 1977. PMID: 588090 Portuguese.
-
An approach to switching patients from baclofen to tizanidine.Hosp Med. 1998 Oct;59(10):778-82. Hosp Med. 1998. PMID: 9850294 Review.
Cited by
-
A benefit-risk assessment of baclofen in severe spinal spasticity.Drug Saf. 2004;27(11):799-818. doi: 10.2165/00002018-200427110-00004. Drug Saf. 2004. PMID: 15350152 Review.
-
Intrathecal baclofen therapy for spasticity: A compliance-based study to indicate effectiveness.Surg Neurol Int. 2016 Aug 2;7(Suppl 19):S539-41. doi: 10.4103/2152-7806.187529. eCollection 2016. Surg Neurol Int. 2016. PMID: 27602250 Free PMC article.
-
Baclofen in the elderly stroke patient its side-effects and pharmacokinetics.Eur J Clin Pharmacol. 1985;29(4):467-9. doi: 10.1007/BF00613463. Eur J Clin Pharmacol. 1985. PMID: 3912190 Clinical Trial.
-
Drugs used to treat spasticity.Drugs. 2000 Mar;59(3):487-95. doi: 10.2165/00003495-200059030-00006. Drugs. 2000. PMID: 10776831 Review.
-
Anti-spasticity agents for multiple sclerosis.Cochrane Database Syst Rev. 2000;2003(4):CD001332. doi: 10.1002/14651858.CD001332. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2001;(4):CD001332. doi: 10.1002/14651858.CD001332. PMID: 11034714 Free PMC article. Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources